Monthly
Flexibility with month-to-month billing.
- Compounded KPV therapy
- Licensed clinician oversight
- Care-team messaging
- Free discreet shipping
KPV is a tripeptide derived from alpha-MSH and studied for its potential anti-inflammatory properties. Truvera’s KPV Therapy is designed to support immune balance and overall wellness.
Potential Benefits
Short Version
A peptide therapy designed to support inflammatory balance and immune health.
Peptide · Inflammatory Support
KPV is a naturally occurring tripeptide derived from alpha-MSH, studied for its ability to quiet the NF-kB signaling pathway at the root of chronic inflammatory conditions. Prescribed by a licensed clinician, compounded to order, and shipped to your door.
How it works
From online intake to medication delivered — in as little as 3 days.
A 5-minute medical intake covers your health history, current symptoms, medications, and inflammatory goals. No appointment needed.
A licensed US clinician reviews your intake and, if clinically appropriate, issues your KPV prescription and compounding order.
Your KPV is compounded at a licensed US pharmacy and shipped in discreet, temperature-controlled packaging.
Message your care team anytime. We monitor your response and adjust your protocol at every check-in.
Pricing
One monthly price covers your clinician visits, compounded medication, shipping, and care team access.
Flexibility with month-to-month billing.
Save 17% vs monthly
Best balance of savings and commitment.
Save 28% vs monthly
Our best price for long-term inflammatory support.
KPV is a compounded peptide, not an FDA-approved drug. Prescriptions are issued only at the discretion of licensed clinicians and only when medically appropriate.
Eligibility
What is KPV?
KPV is a tripeptide — three amino acids (lysine, proline, valine) — representing the active C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide produced in the body. Researchers identified that this short sequence retains the powerful anti-inflammatory properties of its parent hormone while shedding the pigmentation and appetite-related effects. Its primary mechanism involves inhibiting NF-kB, a transcription factor that acts as a master switch for pro-inflammatory gene expression, reducing downstream cytokines including TNF-a, IL-1b, and IL-6.
Preclinical research, including studies published in Gastroenterology, has examined KPV in models of inflammatory bowel disease, skin inflammation, and wound healing. In gut applications, KPV is transported into intestinal cells via the PepT1 transporter — a pathway upregulated during active IBD — where it can accumulate and dampen inflammatory signaling directly. KPV has not yet completed human clinical trials and is not FDA-approved as a standalone drug. It is available through licensed clinicians via Section 503A compounding pharmacies.
Patient experience
"I've dealt with gut inflammation for years — every flare was unpredictable. After two months on KPV I've had my longest stretch without symptoms. The intake was easy and my clinician actually explained the science."
"My dermatologist couldn't get my skin under control. Within six weeks the redness and flares were noticeably calmer. No side effects I could detect."
"I appreciated that TruVera was upfront that this is a compounded peptide, not a magic pill. The care team checked in consistently and my inflammatory markers improved on my last labs."
FAQ
KPV is a tripeptide (lysine-proline-valine) derived from alpha-melanocyte-stimulating hormone, studied for anti-inflammatory properties. It is not FDA-approved as a standalone drug. TruVera provides KPV through licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act — available only with a valid prescription from a licensed clinician.
Clinical interest in KPV centers on chronic inflammatory conditions including inflammatory bowel disease (Crohn's, ulcerative colitis), irritable bowel syndrome, inflammatory skin conditions (psoriasis, eczema, rosacea, acne), and general systemic inflammation. It has also been studied in wound healing and tissue repair contexts. A clinician will determine whether KPV is appropriate for your specific situation.
KPV can be compounded in several forms depending on your clinical needs: oral capsules (most common for gut-focused applications), subcutaneous injection (for systemic effects), or topical formulation (for skin conditions). Your care team will specify the dose and route during your consultation.
Some patients report improvements within 3–7 days; more significant changes are typically observed over 4–8 weeks of consistent use. Peptide therapy responses vary considerably by individual, baseline inflammation level, and indication. Your clinician will evaluate your progress at regular check-ins.
KPV has a favorable tolerability profile in preclinical studies, without the immune-suppressing effects of corticosteroids. Reported mild effects include temporary injection-site reactions (for injectable formulations) and brief digestive adjustment for oral capsules. Long-term human safety data is limited given the absence of completed clinical trials. Your clinician will review your full health history before prescribing.
Yes. You can pause or cancel at any time through your TruVera patient portal — no phone calls, no cancellation fees. If you have questions about your protocol before canceling, your care team is always available to discuss adjustments.